Medina VDA, Verazaluce RBE, Gutiérrez MA, Mundo NPA

Language: Spanish
References: 15
Page: 211-215
PDF size: 225.58 Kb.

ABSTRACT

The CDK4/6 inhibitors represent a recent class of targeted therapy, with expanding indications in both advanced and early-stage hormone receptor-positive, HER2-negative breast cancer. While their safety profile is well established, dermatologic adverse events remain rare and underreported. We present the case of a patient with luminal b breast cancer treated with ribociclib, letrozole, and goserelin, who developed hypopigmented skin lesions with clinical features consistent with vitiligo, a cutaneous adverse effect infrequently described in association with this drug class.

REFERENCES

1. Instituto Nacional de Estadística y Geografía (INEGI), Estadísticasa propósito del Día Internacional de la Lucha Contra el Cáncerde Mama (19 de octubre). Comunicado de prensa núm. 599/24,16 de octubre de 2024. Disponible en: https://www.inegi.org.mx/contenidos/saladeprensa/aproposito/2024/EAP_LuchaCMama24.pdf.

2. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, ImSA et al., Overall survival with ribociclib plus fulvestrant in advancedbreast cancer, New England Journal of Medicine 2020; 382(6):514-24. Disponible en: http://dx.doi.org/10.1056/

3. Fasching PA, Decker T, Hartkopf A, Nusch A, Heinrich BJ, KurbacherC, et al., Efficacy, safety, and prognosis prediction in patientstreated with ribociclib in combination with letrozole: finalresults of phase 3b ribecca study in hormone receptor positive,human epidermal growth factor receptor-2 negative, locallyadvanced or metastatic breast cancer, European Journal ofCancer 2024; 198(113480):113480. Disponible en: http://dx.doi.org/10.1016/j.ejca.2023.113480.

4. Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-BudnyB, Stroyakovskiy D et al., Ribociclib plus endocrine therapy inearly breast cancer, N Engl J Med 2024; 390(12):1080-91. doi:10.1056/NEJMoa2305488.

5. Arenas R. Dermatología. Atlas, diagnóstico y tratamiento, 8ª ed.México, McGraw-Hill, 2024, pp. 122-128.

6. Sollena P, Nikolaou V, Soupos N, Kotteas E, Voudouri D, StratigosAJ et al., Vitiligo-like lesions in patients with advanced breastcancer treated with cycline-dependent kinases 4 and 6 inhibitors,Breast Cancer Res Treat 2021; 185(1):247-53. Disponibleen: http://dx.doi.org/10.1007/s10549-020-05914-w.

7. Guan X, Li M, Ji X, Wang Y y Tian L, Confirming the efficacy andsafety of cdk4/6 inhibitors in the first-line treatment of hr+ advancedbreast cancer: a systematic review and meta-analysis,Front Pharmacol 2024; 15:1369420. Disponible en: http://dx.doi.org/10.3389/fphar.2024.1369420.

8. fda approves ribociclib with an aromatase inhibitor and ribocicliband letrozole co-pack for early high-risk breast cancer, U.S. Foodand Drug Administration, 17 de septiembre de 2024. Disponibleen: https://www.fda.gov/drugs/resources-information-approveddrugs/fda-approves-ribociclib-aromatase-inhibitor-and-ribocicliband-letrozole-co-pack-early-high-risk-0.

9. Schneeweiss A, Ettl J, Lüftner D, Beckmann MW, Belleville E,Fasching PA et al., Initial experience with cdk4/6 inhibitor-basedtherapies compared to antihormone monotherapies in routineclinical use in patients with hormone receptor positive, her2negative breast cancer. Data from the praegnant research networkfor the first 2 years of drug availability in Germany, Breast2020; 54:88-95. Disponible en: http://dx.doi.org/10.1016/j.breast.2020.08.011.

10. Silvestre Torner N, Aguilar Martínez A, Echarri González MJ, TabbaraCarrascosa S, Román Sáinz J y Gruber Velasco F, Ribociclib-induced vitiligo: a case report, Dermatol Pract Concept 2022;e20220045. Disponible en: http://dx.doi.org/10.5826/dpc.1202a45.

11. Coelho JQ, Romão R, Sousa MJ, Azevedo SX, Fidalgo P y AraújoA, Vitiligo-like lesions as a predictor of response to immunotherapyin non-small cell lung cancer: comprehensive review and caseseries from a university center, Curr Oncol 2024; 31(2):1113-28.Disponible en: http://dx.doi.org/10.3390/curroncol31020083.

12. Pasqualoni M, Orlandi A, Palazzo A, Garufi G, Cannizzaro MC,Pontolillo L et al., Case report: vitiligo-like toxicity due to ribociclibduring first-line treatment of metastatic breast cancer:two cases of premature interruption of therapy and exceptionalresponse, Front Oncol 2023; 13:1067264. Disponible en: http://dx.doi.org/10.3389/fonc.2023.1067264.

13. Rao H, Guo Z, Wen X, Zeng X, Wu L y Huang L, Case report:immune checkpoint inhibitor-related vitiligo-like depigmentationin non-melanoma advanced cancer: a report of three casesand a pooled analysis of individual patient data, Front Oncol2022; 12:1099108. Disponible en: http://dx.doi.org/10.3389/fonc.2022.1099108.

14. Borroni RG, Bartolini M, Gaudio M, Jacobs F, Benvenuti C,Gerosa R et al., Ribociclib-induced cutaneous adverse eventsin metastatic hr+/her2- breast cancer: incidence, multidisciplinarymanagement, and prognostic implication, Oncologist2024; 29(6):484-92. Disponible en: http://dx.doi.org/10.1093/oncolo/oyae004.

15. Sharaf B, Al-Masri R, Abdel-Razeq N, Salama O, Hamad I, AbunasserM et al., Vitiligo-like lesions in a patient with metastaticbreast cancer treated with cyclin-dependent kinase (cdk) 4/6 inhibitor:a case report and literature review, Clin Cosmet InvestigDermatol 2022; 15:5-10. doi: 10.2147/CCID.S344867.